Changes in the medial prefrontal cortex metabolites after 6 months of medication therapy for patients with bipolar disorder: A 1 H ‐ MRS study
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.70048 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Haijin Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Bipolar Disorder, Prefrontal Cortex, Aspartic Acid, Proton Magnetic Resonance Spectroscopy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suzhou Key Clinical Treatment Project of China, Henan Young and Middle-aged Health Science and Technology Innovation Talent Training Program of China, Suzhou clinical Medical Center for mood disorders of China.
Abstract (Originalsprache)
Aims
The study aimed to assess brain metabolite differences in the medial prefrontal cortex (mPFC) between acute and euthymic episodes of bipolar disorder (BD) with both mania and depression over a 6‐month medication treatment period.
Methods
We utilized 1 H‐MRS technology to assess the metabolite levels in 53 individuals with BD (32 in depressive phase, 21 in manic phase) and 34 healthy controls (HCs) at baseline. After 6 months of medication treatment, 40 subjects underwent a follow‐up scan in euthymic state. Metabolite levels, including N‐acetyl aspartate (NAA), glutamate (Glu), and Glutamine (Gln), were measured in the mPFC.
Results
Patients experiencing depressive and manic episodes exhibited a notable reduction in NAA/Cr + PCr ratios at baseline compared to healthy controls ( p = 0.004; p = 0.006) in baseline, compared with HCs. Over the 6‐month follow‐up period, the manic group displayed a significant decrease in Gln/Cr + PCr compared to the initial acute phase ( p = 0.03). No significant alterations were found in depressed group between baseline and follow‐up.
Conclusion
This study suggests that NAA/Cr + PCr ratios and Gln/Cr + PCr ratios in the mPFC may be associated with manic and depressive episodes, implicating that Gln and NAA might be useful biomarkers for distinguishing mood phases in BD and elucidating its mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Geriatric Psychiatry, Suzhou Mental Health Center, Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University, Suzhou, China.
- Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Förderung
- Suzhou Key Clinical Treatment Project of China
- Henan Young and Middle-aged Health Science and Technology Innovation Talent Training Program of China
- Suzhou clinical Medical Center for mood disorders of China
- Henan Health Commission of China
- Suzhou Key Science and Technology Project of China
- Suzhou Key clinical medical disciplines project of China
- National Natural Science Foundation of China
- Henan Scientific and Technological Development Program of China
Zitieren
APA
Li, H., Gao, J., Song, H., Yang, X., Li, C., Zhang, Y., Wang, J., Liu, Y., Wang, D., & Li, H. (2024). Changes in the medial prefrontal cortex metabolites after 6 months of medication therapy for patients with bipolar disorder: A 1 H ‐ MRS study. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70048
Vancouver
Li H, Gao J, Song H, Yang X, Li C, Zhang Y, et al. Changes in the medial prefrontal cortex metabolites after 6 months of medication therapy for patients with bipolar disorder: A 1 H ‐ MRS study. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.70048
BibTeX
@article{Li2024,
author = {Li, Haijin and Gao, Ju and Song, Huihui and Yang, Xuna and Li, Cai and Zhang, Yue and Wang, Jiahui and Liu, Yitong and Wang, Dong and Li, Hong},
title = {Changes in the medial prefrontal cortex metabolites after 6 months of medication therapy for patients with bipolar disorder: A 1 H ‐ MRS study},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.70048}
}
EUVIMED